Discover an in vitro tumor model with in vivo-like heterogeneity
Meet InSphero Oncology Platform Product Manager Dr. Francesca Chiovaro at the 25th Biennial Congress of the European Association for Cancer Research in Amsterdam. Dr. Chiovaro will be available throughout the congress to discuss the latest advances in 3D in vitro tumor models derived from PDX material and how you can apply InSphero PDX microtissues to:
- Screen and profile drug candidates using cost effective PDX-derived 3D in vitro models that recapitulate the heterogeneity of tumor microenvironments
- Conduct assays for biomarker discovery and disease-oriented drug development using relevant 3D models chosen for generic alteration or tumor type
- Preselect agents of interest for further preclinical development with an oncology tool designed to reduce research costs and optimize human tumor material.
Screen Targeted Molecular Therapeutics with PDX-derived Models
Poster Title: Development and Characterization of PDX-derived 3D Tumor Microtissues as a Platform for Screening Targeted Molecular Therapeutics”Date/Time:Monday, July 2, 2018, 10:05-17:15
Poster Board Number: PO-441
Abstract Number: 1 010
Dr. Chiovaro will present work on how Patient-derived xenograft (PDX) models act as vehicle systems to propagate human tumor specimens, faithfully preserving the biological features and the genetic expression profile. She will show that development and characterization of in vitro 3D InSight™ Tumor Microtissues from patient-derived xenograft (PDX) lines demonstrate that the morphological and molecular features of the parental tumors are well retained. We suggest that in vitro 3D PDX models offer a more suitable and robust approach to expedite faithful efficacy assessment and approval of optimal drug candidates.